boehringer glp-1 We've covered the Foundayo vs Wegovy rivalry. The FDA safety concerns. The record Kailera IPO. A manufacturer with zero sterility controls. Now a third mechanism enters the obesity race. Ingelheim and Weight loss drugs: Boehringer Ingelheim,

That might show up as a great result on the scale, but it leaves people metabolically weaker, not stronger

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

This blog post by Hormone Fitness explains tirzepatide's unique mechanism of action in clear, easy-to-understand language

Welcome to Blue Cross and Blue Shield of Illinois Medicare Prescription Drug Plan.